sheila RHEUMarampa
6 days 22 hours ago
One of the main changes in the 2025 update on the EULAR guidelines for imaging in SpA is that of MRI replacing CR as the initial imaging modality while CR & low dose CT of SIJs became alternative modalities in the absence of or if with CIs to MRI
AbsPOS0682 @RheumNow #EULAR2026 https://t.co/bj2NWKnIGf
Antoni Chan MD (Prof) synovialjoints
6 days 22 hours ago
Treat-to-target in inflammatory arthritis recommended by every guideline. Followed in only 40% of SpA visits.
The main reason was activity simply wasn’t documented using a validated index.
You can’t target what you don’t measure.
Abstr 0351 @ RheumNow #EULAR2026
#axSpA #PsA https://t.co/VAcoZfCXsR
Day two at EULAR 2026 was jammed with sessions on advances in immune checkpoint inhhbitors (and irAEs), Lupus, Scleroderma, RA and IgG4 related disease. Here are a few of my favorites from Day 2.
Jiha Lee JihaRheum
1 week ago
Getting #RA and IA diagnosed faster: UK RheumACaN program (integrated education + pathway redesign) ↑ clinician confidence 4.4 to 8.6/10. Referral within 3 days: 52% → 70%, with sustained improvement. Education that translates to real outcomes. @RheumNow #EULAR2026 POS0784 https://t.co/1Va9rkLBHM
Antoni Chan MD (Prof) synovialjoints
1 week ago
Proud to present POS0784 at #EULAR2026.
RheumACaN education + pathway redesign across primary and secondary care improved early inflammatory arthritis referrals within 3 working days from 52% to 70%, exceeding the national benchmark.
95% of clinicians changed their practice. https://t.co/W6VViVRndp
RA-ILD remains one of the most serious extra-articular manifestations of RA, contributing substantially to morbidity and mortality. Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin disease development.
Nelly ZIADE 🍀 Nellziade
1 week ago
⏰ The question rheumatologists keep asking: Does early axSpA diagnosis reduce long-term spinal damage?
Answer from the SCQM registry (n=376): Early diagnosis linked to 3.85 fewer mSASSS points long-term, esp. in HLA-B27+ males
#POS0191 #EULAR2026 @RheumNow https://t.co/HM5kvqXMEh
Nelly ZIADE 🍀 Nellziade
1 week ago
📋 Do 2025 ASAS-SPARTAN criteria classify fewer real-world axSpA patients?
Data from the RABBIT-SpA registry (n=2,236) confirms:
67% vs 73% with 2009 criteria
Clinical arm rarely fulfilled
#POS0190 #EULAR2026 @RheumNow https://t.co/HYie4w8c6r
Dr. John Cush RheumNow
1 week ago
DAY 1 & 2 Recap: EULAR 2026 Highlights https://t.co/uVMerChWN6
Nelly ZIADE 🍀 Nellziade
1 week ago
☂️What is an umbrella meta-analysis?
It's a meta-analysis of meta-analyses ☔️
⬇️This one showed the effect of diet supplementation on several RA outcomes
Unfortunately, most studies have low levels of evidence
#umbrella #rainy_London #EULAR2026 @rheumnow https://t.co/kYPchXEexn
Presented at EULAR 2026 London, Brepocitinib dual TYK2/JAK1 inhibitor with successful Phase 3 VALOR trial demonstrating significant improvement in skin and muscle symptoms in dermatomyositis (DM).
